158 related articles for article (PubMed ID: 36979383)
1. Peptide-Based siRNA Nanocomplexes Targeting Hepatic Stellate Cells.
Lin CY; Mamani UF; Guo Y; Liu Y; Cheng K
Biomolecules; 2023 Feb; 13(3):. PubMed ID: 36979383
[TBL] [Abstract][Full Text] [Related]
2. Development of a peptide-modified siRNA nanocomplex for hepatic stellate cells.
Zhao Z; Li Y; Jain A; Chen Z; Liu H; Jin W; Cheng K
Nanomedicine; 2018 Jan; 14(1):51-61. PubMed ID: 28890106
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Peptide ligands for hepatic stellate cells using phage display.
Chen Z; Jin W; Liu H; Zhao Z; Cheng K
Mol Pharm; 2015 Jun; 12(6):2180-8. PubMed ID: 25955351
[TBL] [Abstract][Full Text] [Related]
4. Targeted Delivery of an siRNA/PNA Hybrid Nanocomplex Reverses Carbon Tetrachloride-Induced Liver Fibrosis.
Jain A; Barve A; Zhao Z; Fetse JP; Liu H; Li Y; Cheng K
Adv Ther (Weinh); 2019 Aug; 2(8):. PubMed ID: 33072857
[TBL] [Abstract][Full Text] [Related]
5. Co-delivery of pirfenidone and siRNA in ZIF-based nanoparticles for dual inhibition of hepatic stellate cell activation in liver fibrotic therapy.
Wang K; Chen H; Qin S; Chen S; Zhang Q; Chen J; Di D; Su G; Yuan Y
Colloids Surf B Biointerfaces; 2023 Nov; 231():113567. PubMed ID: 37797465
[TBL] [Abstract][Full Text] [Related]
6. Development of streptavidin-based nanocomplex for siRNA delivery.
Shukla RS; Tai W; Mahato R; Jin W; Cheng K
Mol Pharm; 2013 Dec; 10(12):4534-45. PubMed ID: 24160908
[TBL] [Abstract][Full Text] [Related]
7. Targeting transdifferentiated hepatic stellate cells and monitoring the hepatic fibrogenic process by means of IGF2R-specific peptides designed
Weber F; Casalini T; Valentino G; Brülisauer L; Andreas N; Koeberle A; Kamradt T; Contini A; Luciani P
J Mater Chem B; 2021 Mar; 9(8):2092-2106. PubMed ID: 33595041
[TBL] [Abstract][Full Text] [Related]
8. Nanoparticle-Mediated RNA Therapy Attenuates Nonalcoholic Steatohepatitis and Related Fibrosis by Targeting Activated Hepatic Stellate Cells.
Zhang C; Teng Y; Li F; Ho W; Bai X; Xu X; Zhang XQ
ACS Nano; 2023 Aug; 17(15):14852-14870. PubMed ID: 37490628
[TBL] [Abstract][Full Text] [Related]
9. Synergetic regulation of kupffer cells, extracellular matrix and hepatic stellate cells with versatile CXCR4-inhibiting nanocomplex for magnified therapy in liver fibrosis.
Wu P; Luo X; Sun M; Sun B; Sun M
Biomaterials; 2022 May; 284():121492. PubMed ID: 35395456
[TBL] [Abstract][Full Text] [Related]
10. PCBP2 siRNA reverses the alcohol-induced pro-fibrogenic effects in hepatic stellate cells.
Shukla RS; Qin B; Wan YJ; Cheng K
Pharm Res; 2011 Dec; 28(12):3058-68. PubMed ID: 21643860
[TBL] [Abstract][Full Text] [Related]
11. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
Li Y; Zhao Z; Lin CY; Liu Y; Staveley-OCarroll KF; Li G; Cheng K
Theranostics; 2021; 11(5):2182-2200. PubMed ID: 33500719
[No Abstract] [Full Text] [Related]
12. CREKA-modified liposomes target activated hepatic stellate cells to alleviate liver fibrosis by inhibiting collagen synthesis and angiogenesis.
Li R; Zhang J; Liu Q; Tang Q; Jia Q; Xiong Y; He J; Li Y
Acta Biomater; 2023 Sep; 168():484-496. PubMed ID: 37392933
[TBL] [Abstract][Full Text] [Related]
13. Effect of distinct ECM microenvironments on the genome-wide chromatin accessibility and gene expression responses of hepatic stellate cells.
Jain I; Brougham-Cook A; Underhill GH
Acta Biomater; 2023 Sep; 167():278-292. PubMed ID: 37343907
[TBL] [Abstract][Full Text] [Related]
14. Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy.
Zhou L; Liang Q; Li Y; Cao Y; Li J; Yang J; Liu J; Bi J; Liu Y
Acta Biomater; 2022 Oct; 152():235-254. PubMed ID: 36087869
[TBL] [Abstract][Full Text] [Related]
15. Hepatic Stellate Cells in Liver Fibrosis and siRNA-Based Therapy.
Omar R; Yang J; Liu H; Davies NM; Gong Y
Rev Physiol Biochem Pharmacol; 2016; 172():1-37. PubMed ID: 27534415
[TBL] [Abstract][Full Text] [Related]
16. Discovery of Aptamer Ligands for Hepatic Stellate Cells Using SELEX.
Chen Z; Liu H; Jain A; Zhang L; Liu C; Cheng K
Theranostics; 2017; 7(12):2982-2995. PubMed ID: 28839458
[TBL] [Abstract][Full Text] [Related]
17. Placental growth factor silencing ameliorates liver fibrosis and angiogenesis and inhibits activation of hepatic stellate cells in a murine model of chronic liver disease.
Li X; Yao QY; Liu HC; Jin QW; Xu BL; Zhang SC; Tu CT
J Cell Mol Med; 2017 Oct; 21(10):2370-2385. PubMed ID: 28378526
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Avidin, Neutravidin, and Streptavidin as Nanocarriers for Efficient siRNA Delivery.
Jain A; Barve A; Zhao Z; Jin W; Cheng K
Mol Pharm; 2017 May; 14(5):1517-1527. PubMed ID: 28026957
[TBL] [Abstract][Full Text] [Related]
19. siRNA- and miRNA-based therapeutics for liver fibrosis.
Zhao Z; Lin CY; Cheng K
Transl Res; 2019 Dec; 214():17-29. PubMed ID: 31476281
[TBL] [Abstract][Full Text] [Related]
20. Autophagy regulates turnover of lipid droplets via ROS-dependent Rab25 activation in hepatic stellate cell.
Zhang Z; Zhao S; Yao Z; Wang L; Shao J; Chen A; Zhang F; Zheng S
Redox Biol; 2017 Apr; 11():322-334. PubMed ID: 28038427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
